ReviewCurrent gastroenterology reports2026
Metabolic Dysfunction-Associated Steatotic Liver Disease in the Aging Population: A Narrative Review of Pathophysiological Synergy, Diagnostic Challenges, and Tailored Management.
Review in Current gastroenterology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition in older adults, yet its management in the geriatric context remains poorly characterized. This review examines the unique pathophysiology, diagnostic challenges, and tailored therapeutic strategies for MASLD in the aging population. RECENT
findingsThe convergence of inflammaging, mitochondrial senescence, and the deteriorating liver-muscle axis drives distinct geriatric MASLD phenotypes, including "Lean MASLD" and post-menopausal sex-reversal. These processes promote progression to metabolic dysfunction-associated steatohepatitis (MASH), the inflammatory stage of the disease. Chronodisruption-potentially mediated by melatonin deficiency and nuclear factor-kappa B activation-has been proposed as a novel driver. Advanced liver fibrosis has been associated with systemic biological aging. Diagnostically, standard Fibrosis-4 index thresholds are unreliable in patients over 65, and "silent cirrhosis" with normal aminotransferases is common. Carbon-ion radiotherapy has emerged as a potentially sarcopenia-friendly treatment option for MASLD-related hepatocellular carcinoma. Managing geriatric MASLD requires a paradigm shift from liver-centric histological targets toward functional longevity. Avoiding the "Sarcopenia Trap," recalibrating non-invasive fibrosis tests with age-adjusted thresholds, promoting alcohol abstinence, and addressing chronodisruption are essential components of a holistic, individualized care framework.
Indexed as
Identifiers
42684528What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.